The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

Provided herein are glycan engineered SARS-CoV-2 RBD polypeptides, fusion polypeptides comprising thereof, and immunogenic compositions comprising thereof. Also provided are methods of administering the RBD polypeptide, fusion polypeptide or immunogenic composition to a subject to elicit an immune response. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.

The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.

The present invention provides a vaccine for rabies virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

It is provided a composition comprising (i) VSVd51-hGM-CSF construct as depicted in SEQ ID NO: 1, (ii) a functional equivalent thereof, or (iii) a nucleotide sequence having at least 70% identity with SEQ ID NO: 1; and a carrier, for treating a solid cancer such as e.g. bladder cancer.

The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.

Provided herein are glycan engineered SARS-CoV-2 RBD polypeptides, fusion polypeptides comprising thereof, and immunogenic compositions comprising thereof. Also provided are methods of administering the RBD polypeptide, fusion polypeptide or immunogenic composition to a subject to elicit an immune response. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.

The present invention pertains to a combination for simultaneous, separate or sequential use which comprises (a) an oncolytic virus and (b) a checkpoint inhibitor and to its use for the treatment of cancer.